ECSP045108A - Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea - Google Patents

Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea

Info

Publication number
ECSP045108A
ECSP045108A EC2004005108A ECSP045108A ECSP045108A EC SP045108 A ECSP045108 A EC SP045108A EC 2004005108 A EC2004005108 A EC 2004005108A EC SP045108 A ECSP045108 A EC SP045108A EC SP045108 A ECSP045108 A EC SP045108A
Authority
EC
Ecuador
Prior art keywords
piperazinurea
derivative
solid formulation
medicinal
medicinal based
Prior art date
Application number
EC2004005108A
Other languages
English (en)
Inventor
Heiko Kranz
Christoph Voelkel
Ralph Lipp
Johannes Tack
Herbert Wiesinger
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP045108A publication Critical patent/ECSP045108A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una formulación sólida para utilizar como medicamento que contiene (2R)-1-((4-cloro-2-(ureido)fenoxi) metil)carbonil-2- metil-4-(4-fluoro- bencil)-piperazina o una de sus sales
EC2004005108A 2001-10-18 2004-05-17 Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea ECSP045108A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152351A DE10152351B4 (de) 2001-10-18 2001-10-18 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat

Publications (1)

Publication Number Publication Date
ECSP045108A true ECSP045108A (es) 2004-06-28

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005108A ECSP045108A (es) 2001-10-18 2004-05-17 Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea

Country Status (23)

Country Link
EP (1) EP1435917A1 (es)
JP (1) JP2005506365A (es)
KR (1) KR20040047920A (es)
CN (1) CN1571660A (es)
AR (1) AR037111A1 (es)
AU (1) AU2002333896B2 (es)
BR (1) BR0213340A (es)
CA (1) CA2463951A1 (es)
CO (1) CO5580740A2 (es)
DE (1) DE10152351B4 (es)
EC (1) ECSP045108A (es)
HR (1) HRP20040435A2 (es)
IL (1) IL161166A0 (es)
MX (1) MXPA04003522A (es)
NO (1) NO20042022L (es)
NZ (1) NZ532287A (es)
PE (1) PE20030472A1 (es)
PL (1) PL367987A1 (es)
RS (1) RS32204A (es)
RU (1) RU2311172C2 (es)
UY (1) UY27500A1 (es)
WO (1) WO2003035037A1 (es)
ZA (1) ZA200403781B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723196A (zh) 2001-06-27 2006-01-18 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
EP1749519A1 (de) 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
HUE029173T2 (hu) * 2006-04-26 2017-02-28 Alphapharm Pty Ltd Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
TR200002248T2 (tr) * 1998-02-05 2000-12-21 Pfizer Products Inc. Yeni dihidroksiheksanoik asit türevleri
ATE400251T1 (de) * 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit

Also Published As

Publication number Publication date
MXPA04003522A (es) 2004-07-23
IL161166A0 (en) 2004-08-31
DE10152351A1 (de) 2003-05-08
BR0213340A (pt) 2004-10-05
CA2463951A1 (en) 2003-05-01
WO2003035037A1 (de) 2003-05-01
NO20042022L (no) 2004-05-14
CN1571660A (zh) 2005-01-26
CO5580740A2 (es) 2005-11-30
UY27500A1 (es) 2003-06-30
RS32204A (sr) 2006-10-27
AU2002333896B2 (en) 2007-07-26
NZ532287A (en) 2007-04-27
KR20040047920A (ko) 2004-06-05
RU2311172C2 (ru) 2007-11-27
AR037111A1 (es) 2004-10-20
RU2004115328A (ru) 2005-06-10
PE20030472A1 (es) 2003-06-16
JP2005506365A (ja) 2005-03-03
HRP20040435A2 (en) 2005-06-30
ZA200403781B (en) 2004-11-29
DE10152351B4 (de) 2005-09-22
EP1435917A1 (de) 2004-07-14
PL367987A1 (en) 2005-03-21
AU2002333896A2 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
UY28342A1 (es) Nuevos compuestos
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
UY28348A1 (es) Compuestos novedosos
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
HN2003000407A (es) Nuevos derivados de fluoroglicosisdos aromaticos, medicamentos que contienen estos compuestos y sus usos.
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY27516A1 (es) Bencimidazoles
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
UY28572A1 (es) Compuestos novedosos
PA8548701A1 (es) Azaindoles
SV2005001979A (es) "pirido[2,3-d]pirimidina-2,4-diaminas como inhibidores de pde 2 " ref. pc25123a
PA8570901A1 (es) Derivados de acil-4-carboxifenilurea, procedimientos para su preparacion y su uso
PA8582801A1 (es) Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
AR045572A1 (es) Una combinacion que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil-3-sulfonamida y un analogo lhrh y/o un bifosfonato
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
AR041339A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
HN2001000235A (es) Derivados puentes de piperazina
UY27500A1 (es) Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea
CR8178A (es) Sistemas de emulsion que contienen derivados de azetidina